Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Takeda (Details)

v3.23.3
Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 01, 2006
Nov. 30, 2020
Feb. 28, 2009
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Licensing and other arrangements                
Revenue from contracts with customers       $ 225 $ 25 $ 1,350 $ 3,300  
Takeda Pharmaceutical Company Limited | Collaboration Agreement                
Licensing and other arrangements                
Maximum eligible milestone payments receivable upon achievement of milestones       16,000   16,000    
Revenue from contracts with customers   $ 2,000   0 $ 0 0 $ 800  
Contract assets       0   0   $ 0
Contract liabilities       0   0   0
Capitalized contract costs       $ 0   $ 0   $ 0
Takeda Pharmaceutical Company Limited | Collaboration Agreement | TAK-079 and TAK-169                
Licensing and other arrangements                
Maximum eligible milestone payments receivable upon achievement of milestones $ 19,000              
Royalty payment period, minimum 13 years 6 months              
Royalty payment period from the first commercial sale of each royalty-bearing discovery product 12 years              
Takeda Pharmaceutical Company Limited | Collaboration Agreement | Other antibodies                
Licensing and other arrangements                
Maximum eligible milestone payments receivable per discovery product candidate     $ 3,300          
Royalty payment period, minimum     10 years